[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100551421":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":11,"centralContacts":31,"locations":40,"responsibleParty":131,"collaborators":11,"id":133,"slug":11,"hasResults":134,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":134,"sex":140,"minAge":141,"maxAge":11,"enrollmentInfo":142,"targetDuration":11,"studyType":145,"phases":146,"briefSummary":148,"conditions":149,"keywords":151,"overallStatus":56,"whyStopped":11,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":163},{"fullName":5,"class":6},"Akamis Bio","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"NG-350A plus CRT during a 12-week active study treatment period","EXPERIMENTAL",null,[13,14,15],"Drug: NG-350A IV administration","Drug: Capecitabine oral administration","Radiation: Radiotherapy",[17,22,26],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":11},"DRUG","NG-350A IV administration","a tumour-selective anti-CD40-expressing adenoviral vector",[9],{"type":18,"name":23,"description":24,"armGroupLabels":25,"otherNames":11},"Capecitabine oral administration","chemotherapy",[9],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":11},"RADIATION","Radiotherapy","long-course intensity-modulated radiotherapy",[9],[32,37],{"name":33,"role":34,"phone":35,"phoneExt":11,"email":36},"Vice President Head of Clinical Operations","CONTACT","+1 (484) 362-8918","robert.maietta@akamisbio.com",{"name":38,"role":34,"phone":11,"phoneExt":11,"email":39},"https:\u002F\u002Fwww.FortressStudy.org","oliver.rosen@akamisbio.com",[41,54,69,82,95,108,120],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":11},"University of Southern California","ACTIVE_NOT_RECRUITING","Los Angeles","California","90033","United States",{"type":49,"coordinates":50},"Point",[51,52],-118.24368,34.05223,{"lat":52,"lon":51},{"facility":55,"status":56,"city":57,"state":58,"zip":59,"country":47,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"AdventHealth Orlando","RECRUITING","Orlando","Florida","32804",{"type":49,"coordinates":61},[62,63],-81.37924,28.53834,{"lat":63,"lon":62},[66],{"name":67,"role":68,"phone":11,"phoneExt":11,"email":11},"Mohamedtaki Tejani","PRINCIPAL_INVESTIGATOR",{"facility":70,"status":56,"city":71,"state":72,"zip":73,"country":47,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Washington University School of Medicine","St Louis","Missouri","63110",{"type":49,"coordinates":75},[76,77],-90.19789,38.62727,{"lat":77,"lon":76},[80],{"name":81,"role":68,"phone":11,"phoneExt":11,"email":11},"Moh'd Khushman",{"facility":83,"status":56,"city":84,"state":85,"zip":86,"country":47,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"Ohio State University Comprehensive Cancer Center","Columbus","Ohio","43210",{"type":49,"coordinates":88},[89,90],-82.99879,39.96118,{"lat":90,"lon":89},[93],{"name":94,"role":68,"phone":11,"phoneExt":11,"email":11},"Eric Miller",{"facility":96,"status":56,"city":97,"state":98,"zip":99,"country":47,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"The University of Texas MD Anderson Cancer Center","Houston","Texas","77030",{"type":49,"coordinates":101},[102,103],-95.36327,29.76328,{"lat":103,"lon":102},[106],{"name":107,"role":68,"phone":11,"phoneExt":11,"email":11},"Sonal Noticewala",{"facility":109,"status":56,"city":110,"state":11,"zip":11,"country":111,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"University College London NHS FT","London","United Kingdom",{"type":49,"coordinates":113},[114,115],-0.12574,51.50853,{"lat":115,"lon":114},[118],{"name":119,"role":68,"phone":11,"phoneExt":11,"email":11},"Maria Hawkins",{"facility":121,"status":56,"city":122,"state":11,"zip":11,"country":111,"cosmosGeoPoint":123,"geoPoint":127,"contacts":128},"The Royal Marsden NHS Foundation Trust","Sutton",{"type":49,"coordinates":124},[125,126],-0.2,51.35,{"lat":126,"lon":125},[129],{"name":130,"role":68,"phone":11,"phoneExt":11,"email":11},"Sheela Rao",{"type":132,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100551421",false,"NCT06459869","NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer","A Multicentre, Open-label, Non-randomized, Phase 1b Trial of NG-350A, a Tumour-selective Anti-CD40-expressing Adenoviral Vector, in Combination With Chemoradiotherapy in Locally Advanced Rectal Cancer (FORTRESS)","FORTRESS","Selected Inclusion Criteria:\n\n* Histologically confirmed adenocarcinoma of the rectum.\n* Locally advanced disease (clinical stage II-III based on pelvic MRI) selected by a multidisciplinary team for treatment with neoadjuvant CRT (which may be followed by CNCT to comprise planned TNT). Patients with oligometastatic disease are permitted provided that the site-specific multidisciplinary team deems them suitable for radical treatment\u002Fchemoradiation.\n* Confirmed microsatellite stable (MSS)\u002Fproficient mismatch repair (pMMR) status.\n* Provide written informed consent to participate.\n* ECOG Performance Status 0 or 1.\n* Must not be pregnant or breastfeeding.\n* Patients who are sexually active (with either sex) must agree to comply with contraceptive requirements.\n* Adequate lung reserve, renal function, hepatic function, and bone marrow\u002Fhematological function assessed ≤ 10 days prior to first dose.\n\nSelected Exclusion Criteria:\n\n* Recurrent rectal cancer.\n* Distant metastatic disease not amenable to radical treatment\u002Fchemoradiation.\n* Other prior malignancy active within the previous 3 years, except for local or organ confined early-stage cancer that has been definitively treated with curative intent, does not require ongoing treatment, has no evidence of residual disease, and has a negligible risk of recurrence and is therefore unlikely to interfere with the primary and secondary endpoints of the trial, including response rate and safety.\n* Splenectomy (patients with prior partial resection remain eligible if the Investigator considers splenic function to not be significantly compromised).\n* Active autoimmune disease that has required systemic therapy in the past 2 years, immunocompromised status in the opinion of the Investigator, or current treatment with systemic immunosuppressive therapy (daily prednisone equivalent for chronic system replacement not to exceed 10mg per day).\n* Infectious or inflammatory bowel disease in the 3 months before the first dose of study treatment.\n* Any clinically significant cardiovascular, peripheral vascular, cerebrovascular, or thromboembolic event in the last 1 month before the first dose of study treatment.\n* Major surgery in the 14 days before the first dose of study treatment or any surgical wounds that are not fully healed and free of infection or dehiscence.\n* Any prior surgery for rectal cancer or pelvic radiotherapy.\n* Any other anti-cancer or experimental therapy within the previous 12 months or that is planned during the active study treatment period.\n* Treatment with any other enadenotucirev-based virus (parent virus or transgene-modified variants), or anti-CD40 antibody at any time.\n* History of prior Grade 3-4 acute kidney injury or other clinically significant renal impairment.\n* Any ongoing Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥2 coagulation abnormality\u002Fcoagulopathy.\n\nURL:\n\nhttps:\u002F\u002Fwww.FortressStudy.org","ALL","18 Years",{"count":143,"type":144},30,"ESTIMATED","INTERVENTIONAL",[147],"PHASE1","The FORTRESS trial (NG-350A-03) is an open-label, single-arm, and multicentre trial of NG-350A in combination with chemoradiotherapy (CRT) in adult patients with locally advanced rectal cancer (LARC) and at least one risk factor for local or distant recurrence.",[150],"Locally Advanced Rectal Cancer (LARC)",[152,153],"Treatment naive","Oligometastatic","2026-06-10",{"date":156,"type":157},"2026-06-12","ACTUAL",{"date":159,"type":157},"2025-04-07",{"date":161,"type":144},"2028-12-30",{"name":5,"class":6},7]